Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 7,570,000 shares, a decline of 6.5% from the July 15th total of 8,100,000 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 5.1 days.

Grifols Trading Up 0.1 %

GRFS opened at $7.19 on Wednesday. The business has a 50 day simple moving average of $7.39 and a two-hundred day simple moving average of $7.24. The firm has a market capitalization of $4.94 billion, a price-to-earnings ratio of 7.12 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 1.29. Grifols has a one year low of $5.30 and a one year high of $12.15.

Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The business had revenue of $1.96 billion for the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. Analysts predict that Grifols will post 0.79 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in Grifols during the 4th quarter valued at approximately $26,137,000. Sei Investments Co. grew its holdings in shares of Grifols by 5.3% during the 1st quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock worth $14,091,000 after acquiring an additional 107,000 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Grifols during the 4th quarter worth approximately $398,000. Team Hewins LLC grew its holdings in shares of Grifols by 11.8% during the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 4,324 shares during the period. Finally, Morningstar Investment Services LLC purchased a new position in shares of Grifols during the 4th quarter worth approximately $186,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.